Allogene Therapeutics, Inc. (ALLO) |
|
10.26 -0.51 (-4.74%)
|
11-28 16:00 |
|
Open: |
10.64 |
Pre. Close: |
10.77 |
|
High:
|
10.87 |
Low:
|
9.95 |
|
Volume:
|
1,322,024 |
Market Cap:
|
1,480(M) |
|
|
|
Technical analysis |
as of: 2022-11-28 4:37:49 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 12.96 One year: 15.14 |
| Support: |
Support1: 9.46 Support2: 8.46 |
| Resistance: |
Resistance1: 11.1 Resistance2: 12.96 |
| Pivot: |
9.9  |
| Moving Average: |
MA(5): 10.52 MA(20): 9.92
MA(100): 12.3 MA(250): 11.23 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 77.3 %D(3): 83.2 |
| RSI: |
RSI(14): 50.1 |
| 52-week: |
High: 19.11 Low: 6.42 |
| Average Vol(K): |
3-Month: 1,796 (K) 10-Days: 1,592 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ALLO ] has closed below upper band by 35.1%. Bollinger Bands are 24.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
10.89 - 10.94 |
10.94 - 10.99 |
|
Low:
|
9.83 - 9.89 |
9.89 - 9.93 |
|
Close:
|
10.18 - 10.27 |
10.27 - 10.34 |
|
Company Description |
|
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California. |
Headline News |
Sun, 27 Nov 2022
Montréal's Rising Star Izzy-S Returns With "Allo c'est qui?" Single: Stream - HotNewHipHop
Fri, 25 Nov 2022
‘Allo, Beirut?’ exhibition reconnects to forgotten past of Lebanon’s capital - The National
Fri, 11 Nov 2022
ALLO recognized for work in hiring veterans - KSNB
Wed, 09 Nov 2022
'Allo! Allo! Will Neyland attend tenth anniversary twinning weekend? - Yahoo News UK
Thu, 03 Nov 2022
Allo commits to continued support of employees serving in Guard, Reserves - North Platte Post
Tue, 01 Nov 2022
Bukalapak, Allo Fresh Collaboration Still Has No Visible Results | D-Insights - Katadata
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
144 (M) |
|
% Held by Insiders
|
8.241e+007 (%) |
|
% Held by Institutions
|
29.7 (%) |
|
Shares Short
|
27,590 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-2.975e+008 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-126 |
|
Return on Assets (ttm)
|
707.6 |
|
Return on Equity (ttm)
|
-19.9 |
|
Qtrly Rev. Growth
|
247000 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
-61.99 |
|
EBITDA (p.s.)
|
-3.07949e+008 |
|
Qtrly Earnings Growth
|
-2.3 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-204 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-4.3 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.17 |
|
Price to Cash Flow
|
1.17 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
3.096e+007 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
